Cargando…

Bacteriophage Therapy: Developments and Directions

In an era of proliferating multidrug resistant bacterial infections that are exhausting the capacity of existing chemical antibiotics and in which the development of new antibiotics is significantly rarer, Western medicine must seek additional therapeutic options that can be employed to treat these...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikolich, Mikeljon P., Filippov, Andrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148498/
https://www.ncbi.nlm.nih.gov/pubmed/32213955
http://dx.doi.org/10.3390/antibiotics9030135
_version_ 1783520606424137728
author Nikolich, Mikeljon P.
Filippov, Andrey A.
author_facet Nikolich, Mikeljon P.
Filippov, Andrey A.
author_sort Nikolich, Mikeljon P.
collection PubMed
description In an era of proliferating multidrug resistant bacterial infections that are exhausting the capacity of existing chemical antibiotics and in which the development of new antibiotics is significantly rarer, Western medicine must seek additional therapeutic options that can be employed to treat these infections. Among the potential antibacterial solutions are bacteriophage therapeutics, which possess very different properties from broad spectrum antibiotics that are currently the standard of care, and which can be used in combination with them and often provide synergies. In this review we summarize the state of the development of bacteriophage therapeutics and discuss potential paths to the implementation of phage therapies in contemporary medicine, focused on fixed phage cocktail therapeutics since these are likely to be the first bacteriophage products licensed for broad use in Western countries.
format Online
Article
Text
id pubmed-7148498
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71484982020-04-20 Bacteriophage Therapy: Developments and Directions Nikolich, Mikeljon P. Filippov, Andrey A. Antibiotics (Basel) Review In an era of proliferating multidrug resistant bacterial infections that are exhausting the capacity of existing chemical antibiotics and in which the development of new antibiotics is significantly rarer, Western medicine must seek additional therapeutic options that can be employed to treat these infections. Among the potential antibacterial solutions are bacteriophage therapeutics, which possess very different properties from broad spectrum antibiotics that are currently the standard of care, and which can be used in combination with them and often provide synergies. In this review we summarize the state of the development of bacteriophage therapeutics and discuss potential paths to the implementation of phage therapies in contemporary medicine, focused on fixed phage cocktail therapeutics since these are likely to be the first bacteriophage products licensed for broad use in Western countries. MDPI 2020-03-24 /pmc/articles/PMC7148498/ /pubmed/32213955 http://dx.doi.org/10.3390/antibiotics9030135 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nikolich, Mikeljon P.
Filippov, Andrey A.
Bacteriophage Therapy: Developments and Directions
title Bacteriophage Therapy: Developments and Directions
title_full Bacteriophage Therapy: Developments and Directions
title_fullStr Bacteriophage Therapy: Developments and Directions
title_full_unstemmed Bacteriophage Therapy: Developments and Directions
title_short Bacteriophage Therapy: Developments and Directions
title_sort bacteriophage therapy: developments and directions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148498/
https://www.ncbi.nlm.nih.gov/pubmed/32213955
http://dx.doi.org/10.3390/antibiotics9030135
work_keys_str_mv AT nikolichmikeljonp bacteriophagetherapydevelopmentsanddirections
AT filippovandreya bacteriophagetherapydevelopmentsanddirections